ClinicalTrials.gov record
Withdrawn Phase 1Phase 2 Interventional

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

ClinicalTrials.gov ID: NCT05936229

Public ClinicalTrials.gov record NCT05936229. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 11:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1/2 Study to Evaluate the Safety, Feasibility, and Efficacy of FP-1201 (Intravenous Interferon-Beta-1a) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Study identification

NCT ID
NCT05936229
Recruitment status
Withdrawn
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Fred Hutchinson Cancer Center
Other
Enrollment
Not listed

Conditions and interventions

Interventions

  • Biopsy Procedure
  • Biospecimen Collection Procedure
  • Bone Marrow Aspiration Procedure
  • Bone Marrow Biopsy Procedure
  • Computed Tomography Procedure
  • Echocardiography Procedure
  • Interferon Beta-1A Biological
  • Lumbar Puncture Procedure
  • Multigated Acquisition Scan Procedure
  • Positron Emission Tomography Procedure
  • X-Ray Imaging Procedure

Procedure · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2025
Primary completion
Oct 29, 2027
Completion
Oct 29, 2027
Last update posted
Jul 11, 2024

2025 – 2027

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Fred Hutch/University of Washington Cancer Consortium Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05936229, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 11, 2024 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05936229 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →